A detailed history of Park National Corp transactions in Astrazeneca PLC stock. As of the latest transaction made, Park National Corp holds 153,221 shares of AZN stock, worth $9.87 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares
153,221
Previous 161,382 5.06%
Holding current value
$9.87 Million
Previous $12.6 Million 5.15%
% of portfolio
0.42%
Previous 0.47%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 01, 2024

SELL
$76.67 - $87.62 $625,703 - $715,066
-8,161 Reduced 5.06%
153,221 $11.9 Million
Q2 2024

Jul 15, 2024

BUY
$66.81 - $80.83 $1.3 Million - $1.58 Million
19,499 Added 13.74%
161,382 $12.6 Million
Q1 2024

Apr 01, 2024

SELL
$61.03 - $69.57 $260,170 - $296,576
-4,263 Reduced 2.92%
141,883 $9.61 Million
Q4 2023

Jan 02, 2024

BUY
$61.89 - $69.28 $445,360 - $498,538
7,196 Added 5.18%
146,146 $9.84 Million
Q3 2023

Oct 02, 2023

SELL
$64.85 - $71.7 $116,794 - $129,131
-1,801 Reduced 1.28%
138,950 $9.41 Million
Q2 2023

Jul 03, 2023

SELL
$69.91 - $75.81 $571,024 - $619,216
-8,168 Reduced 5.48%
140,751 $10.1 Million
Q1 2023

Apr 03, 2023

SELL
$63.15 - $71.6 $119,100 - $135,037
-1,886 Reduced 1.25%
148,919 $10.3 Million
Q4 2022

Feb 06, 2023

BUY
$54.21 - $70.44 $3.8 Million - $4.93 Million
70,057 Added 86.76%
150,805 $10.2 Million
Q3 2022

Oct 03, 2022

SELL
$53.02 - $135.75 $56,625 - $144,981
-1,068 Reduced 1.31%
80,748 $4.43 Million
Q2 2022

Jul 01, 2022

SELL
$59.26 - $71.14 $838,766 - $1.01 Million
-14,154 Reduced 14.75%
81,816 $5.41 Million
Q1 2022

Apr 01, 2022

SELL
$55.72 - $67.12 $761,915 - $917,798
-13,674 Reduced 12.47%
95,970 $6.37 Million
Q4 2021

Jan 04, 2022

SELL
$54.02 - $63.83 $1.38 Million - $1.63 Million
-25,588 Reduced 18.92%
109,644 $6.39 Million
Q3 2021

Oct 01, 2021

SELL
$55.56 - $60.79 $1.73 Million - $1.89 Million
-31,151 Reduced 18.72%
135,232 $8.12 Million
Q2 2021

Jul 01, 2021

SELL
$48.42 - $60.18 $6.95 Million - $8.64 Million
-143,512 Reduced 46.31%
166,383 $9.97 Million
Q1 2021

Apr 01, 2021

BUY
$47.16 - $54.44 $28,814 - $33,262
611 Added 0.2%
309,895 $15.4 Million
Q4 2020

Jan 04, 2021

BUY
$48.52 - $58.02 $307,859 - $368,136
6,345 Added 2.09%
309,284 $15.5 Million
Q3 2020

Oct 01, 2020

SELL
$53.07 - $61.1 $115,480 - $132,953
-2,176 Reduced 0.71%
302,939 $16.6 Million
Q2 2020

Jul 01, 2020

SELL
$43.1 - $55.31 $546,249 - $700,998
-12,674 Reduced 3.99%
305,115 $16.1 Million
Q1 2020

Apr 01, 2020

BUY
$37.79 - $51.33 $113,899 - $154,708
3,014 Added 0.96%
317,789 $14.2 Million
Q4 2019

Jan 02, 2020

BUY
$42.46 - $50.46 $427,911 - $508,535
10,078 Added 3.31%
314,775 $15.7 Million
Q3 2019

Oct 01, 2019

BUY
$40.12 - $45.47 $1.06 Million - $1.2 Million
26,426 Added 9.5%
304,697 $13.6 Million
Q2 2019

Jul 01, 2019

BUY
$37.28 - $41.68 $1.51 Million - $1.68 Million
40,391 Added 16.98%
278,271 $11.5 Million
Q1 2019

Apr 01, 2019

BUY
$35.49 - $43.02 $2.21 Million - $2.68 Million
62,399 Added 35.56%
237,880 $9.62 Million
Q4 2018

Jan 02, 2019

BUY
$36.86 - $41.49 $3.69 Million - $4.15 Million
100,111 Added 132.83%
175,481 $6.67 Million
Q3 2018

Oct 02, 2018

BUY
$34.76 - $39.72 $2.62 Million - $2.99 Million
75,370 New
75,370 $2.98 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Park National Corp Portfolio

Follow Park National Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park National Corp , based on Form 13F filings with the SEC.

News

Stay updated on Park National Corp with notifications on news.